biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
biote Corp.NASDAQ: BTMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $2.28M fell 85.6% year over year, behind the +29.7% change in trailing-twelve-month net income. Sequentially, it fell 13.0% from the prior quarter. Over 3 fiscal years it compounded at +173.4% a year.
Context
- Net income amounted to 14.1% of revenue in FY2025, up 14.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $984.33K (-96.4%) for the fiscal year ending Dec 2026, a slowdown from the +58693.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.28M-13.0% QoQ
- Last fiscal yearDec 2025
- $27.05M+58693.5% YoY
- LTMMar 2026
- $18.04M+29.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 27.05M USD
- Year-over-year change
- +58693.5%
- 4-year CAGR
- -4.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.05M | +58693.5% |
| FY2024 | 2024-12-31 | 46K | -98.6% |
| FY2023 | 2023-12-31 | 3.32M | +150.5% |
| FY2022 | 2022-12-31 | 1.32M | -95.9% |
| FY2021 | 2021-12-31 | 32.62M | — |
Net Income vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 net income of $18.04M is the 8th largest of the 11 companies compared; the peer median is $65.92M.
- Its year-over-year change of +29.7% is the 6th highest of 11, against a peer median of +59.6%.
- Net income amounts to 9.6% of revenue for BTMD, versus a peer median of 575.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.68B | +43056.2% | +1.1% | 519699.0% | |
| LTM Mar 2026 | $883.08M | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $380.63M | +410.8% | +148.5% | 1124.1% | |
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $18.04M | +29.7% | +173.4% | 9.6% | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| LTM Mar 2026 | $11.06M | -80.5% | -9.9% | 9.5% | |
| LTM Mar 2026 | $2.31M | +126.6% | +66.8% | 4.1% | |
| Peer median (excluding BTMD) | $65.92M | +59.6% | +22.4% | 575.9% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 32.62M | 1.32M | 3.32M | 46K | 27.05M |
| Depreciation & Amortization | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M |
| Deferred Income Tax | 0 | (743K) | 721K | (2.9M) | 3.98M |
| Stock-Based Compensation | 0 | 82.18M | 9.06M | 8.74M | 8.92M |
| Change in Working Capital | (1.46M) | (35.81M) | (8.93M) | 9.93M | (8.25M) |
| Accounts Receivables | (752K) | (1.56M) | (505K) | (2.27M) | (958K) |
| Inventory | (5.76M) | (1.71M) | (6.1M) | 3.71M | (6.24M) |
| Accounts Payables | 1.61M | 416K | (165K) | 1.55M | 1.01M |
| Other Working Capital | 3.45M | (32.96M) | (2.16M) | 6.94M | (2.06M) |
| Other Non-Cash Items | 1.16M | (58.3M) | 19.72M | 25.85M | (165K) |
| Operating Cash Flow | 33.72M | (9.16M) | 26.88M | 45.24M | 35.19M |
| Capital Expenditures | (3.81M) | (1.84M) | (2.71M) | (6.43M) | (5.02M) |
| Acquisitions (Net) | 0 | 0 | 0 | (11.84M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2.36M) | (1.51M) | (2.35M) | (526K) | (1.85M) |
| Investing Cash Flow | (3.81M) | (1.84M) | (2.71M) | (18.8M) | (6.86M) |
| Debt Repayment | (5M) | 84.38M | (6.25M) | (6.25M) | (1.25M) |
| Common Stock Issued | 0 | 442K | 144K | 282K | 368K |
| Common Stock Repurchased | 0 | (424K) | 0 | (5.6M) | (3.37M) |
| Dividends Paid | (11.4M) | (12.89M) | (8.69M) | (4.74M) | (1.73M) |
| Other Financing Activities | (3.94M) | (8.05M) | 420K | (59.77M) | (37.58M) |
| Financing Cash Flow | (20.34M) | 63.46M | (14.38M) | (76.08M) | (43.56M) |
| Effect of Forex Changes | (12K) | 0 | (19K) | (22K) | 6K |
| Net Change in Cash | 9.56M | 52.47M | 9.77M | (49.66M) | (15.22M) |
| Free Cash Flow | 29.91M | (11M) | 24.17M | 38.81M | 30.18M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.